Document:

<PAGE>   1
                                                                     EXHIBIT 4.7

                               SECURITY AGREEMENT

         THIS SECURITY AGREEMENT (this "Agreement") made this August __, 2001
between American Biogenetic Sciences, Inc., a Delaware corporation (the
"Company") and Biotechnology Value Fund, L.P., Biotechnology Value Fund II,
L.P., Investment 10 L.L.C. and BVF Investments, L.L.C. ("Secured Parties").

SECTION 1.        SECURITY INTEREST.

         The Company hereby grants to Secured Parties a security interest (the
"Security Interest") in the Collateral, as hereafter defined. Capitalized terms
used herein without definition shall have the meanings ascribed to them in the
Revenue Participation Notes, dated as of August __, 2001 (the "Revenue
Participation Notes").

SECTION 2.        COLLATERAL.

         The property in which the Security Interest is hereby granted is the
following: (a) an undivided 25% interest in all of the Company's rights to the
payment of royalty payments under the Abbott License Agreement (the "Royalty
Rights") (B) an undivided 25% interest in all payments actually paid to the
Company on account of the Royalty Rights (the "Royalty Payments"), (C) the
account designated for the benefit of the Secured Parties under the "Trust
Account" as described in Section 4 below, and (D) the proceeds of any of the
foregoing, as "proceeds" are defined by the Uniform Commercial Code
(collectively hereafter referred to as the "Collateral").

SECTION 3.        OBLIGATIONS SECURED.

         The Security Interest shall secure the payment and performance of the
Company's obligations set forth in the Revenue Participation Notes to pay the
Secured Parties, as and when received by the Company, 25% of each of the Abbott
Royalty Payments (the "Obligations") in an amount up to the Aggregate Payment
Amount, as described in the Revenue Participation Agreement.

SECTION 4.        FINANCING STATEMENTS AND OTHER ACTION.

         (a) The Company agrees to do all acts which the Secured Parties deem
reasonably necessary or desirable to protect the Security Interest or to
otherwise carry out the provisions of this Agreement, including the execution of
financing, continuation, amendment and termination statements and other notices
appropriate under law in form satisfactory to the Company and the Secured
Parties. The Company will pay the cost of filing the same in all public offices.

         (b) The Company and the Secured Parties agree that the Form UCC-1, and
any continuation statements thereof, to be filed by the Secured Parties to
perfect the Security Interest shall be substantially in the form attached hereto
as Exhibit A.

Security Agreement

<PAGE>   2

         (c ) All Royalty Payments shall, upon receipt by the Company, be
deposited into a separate, segregated, interest-paying account maintained by a
commercial bank insured by the FDIC (the "Trust Account"). Upon receipt, the
bank shall immediately credit 25% of such Royalty Payment to an account to be
held in trust for the benefit of Secured Parties, and shall credit 75% to an
account for the benefit of the Company. The Company may transfer the amounts
from the 75% account to itself and shall direct the bank to transfer the amounts
from the Secured Parties account to such Secured Parties in accordance with
their respective interests in the Royalty Payments in accordance with the
Revenue Participation Notes. The Trust Account shall be opened by the Company no
later than the first business day after it receives its first Royalty Payment.
Upon creation of the Trust Account, the Company shall cooperate with Secured
Parties in the creation and execution of a Control Agreement, upon such
reasonable terms as are acceptable to the bank at which the Trust Account is
maintained, so as to perfect the security interest of the Secured Parties in
their 25% account of the Trust Account.

SECTION 5.        THE COMPANY'S PLACE OF ORGANIZATION AND PLACE(S) OF BUSINESS.

         (a) The Company warrants that the Company is incorporated as a business
corporation under the laws of the State of Delaware and its exact legal name is
American Biogenetic Sciences, Inc.

         (b) The Company covenants to notify the Secured Parties of any change
in the information contained in this Section.

SECTION 6.        ENCUMBRANCES.

         (a) The Company warrants that the Company has title to the Collateral
and that there are no claims, liens, security interests or other encumbrances.

         (b) The Company covenants that it will maintain its corporate existence
in the jurisdiction specified in Section 5 and will maintain such existence in
good standing.

         (c) The Company covenants to comply with all laws and regulations of
the United States or of any state thereof or of any political subdivision
thereof, or of any governmental authority which may be applicable to it or to
its business.

SECTION 7.        MAINTENANCE OF COLLATERAL.

         The Company shall preserve the Collateral for the benefit of the
Secured Parties. Without limiting the generality of the foregoing, the Company
shall take commercially reasonable steps to collect all royalties payable by
Abbott under the Abbott License Agreement.

SECTION 8.        MAINTENANCE OF RECORDS; REPORTS.

         The Company covenants to keep at all times accurate and complete
records listing and describing the payments received from Abbott under the
Abbott License Agreement. The Secured Parties shall have the right at any time
to call at the Company's place of business and to

                                       2
Security Agreement

<PAGE>   3

inspect and to audit and make copies of any records or other writings which
relate to the Collateral.

SECTION 9.        DEFAULT.

         (a)      It shall be an Event of Default if:

                  any representation or warranty made by the Company under the
Revenue Participation Notes shall prove to have been false in any material
respect upon the date when made;

                  the Company fails to pay any amounts due under any of the
Obligations when due and such failure continues for a period of 30 days;

                  (i) the Company fails to observe or perform any covenant,
warranty or agreement to be performed by the Company under this Agreement or
the Revenue Participation Notes or any breaches any representation, warranty or
covenant relating to the Revenue Participation Notes in the Securities Purchase
Agreement, and such breach or failure continues for a period of 30 days after
the Secured Parties give written notice of such breach or failure to the
Company.

                  (ii) If an Event of Default occurs while any Obligations are
outstanding, the Secured Parties may declare the Company in default and exercise
the Rights on Default as hereinafter defined.

SECTION 10.       RIGHTS ON DEFAULT.

         (a) If an Event of a Default occurs under this Agreement, the Secured
Parties may exercise the following Rights on Default:

                  (i)  exercise the rights and remedies accorded a secured
party by the Uniform Commercial Code or by any document securing the
Obligations;

                  (ii) perform any warranty, covenant or agreement which the
Company has failed to perform under this Agreement, the Revenue Participation
Notes, or the Securities Purchase Agreement; and

                  (iii) take any other action which the Secured Parties deem
necessary or desirable to protect the Collateral or the Security Interest.

         (b) No course of dealing or delay in taking or failing to take any
other action with respect to any Event of Default shall affect the Secured
Parties' right to take such action at a later time. No waiver as to any one
Event of Default shall affect the Secured Parties' Rights on Default upon any
other Event of Default. The Secured Parties may exercise any or all of its
Rights on Default concurrently with or independently of and without regard to
the provisions of any other document which secures an Obligation.

                                       3
Security Agreement
<PAGE>   4

         (c) The requirement of the Uniform Commercial Code that the Secured
Parties give the Company reasonable notice of any proposed sale or disposition
of the Collateral shall be met if such notice is given to the Company at least
ten days before the time of such sale or disposition.

         (d) If an Event of a Default occurs under this Agreement, the present
value of the Obligations (i.e. 25% of each of the Abbott Royalty Payments, as
and when received by the Company) under the Revenue Participation Notes secured
hereby shall be determined by an independent valuation firm or appraiser
experienced in valuing such obligations such as the Secured Parties select in
good faith.

SECTION 11.       EXPENSES.

         Any payment made or expense incurred by the Secured Parties (including,
without limitation, reasonable attorneys' fees and disbursements) in connection
with the exercise of any Right on Default, shall be added to the indebtedness of
the Company to the Secured Parties, shall be payable upon demand and shall be
secured by the Security Interest.

SECTION 12.       TERM.

         The term of this Agreement shall commence on the date hereof and shall
continue in full force and effect and be binding upon the Company until all
Obligations of the Company to the Secured Parties shall have been fully paid and
satisfied.

SECTION 13.       NOTICES.

         All notices, requests, consents and other communications hereunder
shall be in writing, shall be addressed to the receiving party's address set
forth in Section 9.1 of the Securities Purchase Agreement or to such other
address as a party may designate by notice hereunder, and shall be either (i)
delivered by hand, (ii) made by telecopy or facsimile transmission, (iii) sent
by recognized national overnight courier service, or (iv) sent by registered
mail, return receipt requested, postage prepaid. All notices, requests, consents
and other communications hereunder shall be deemed to have been given either (i)
if by hand, at the time of the delivery thereof to the receiving party at the
address of such party set forth above, (ii) if made by telecopy or facsimile
transmission, one day after the time that receipt thereof has been acknowledged
by electronic confirmation or otherwise, (iii) if sent by overnight courier, on
the next business day following the day such notice is delivered to the courier
service, or (iv) if sent by registered mail, on the fifth business day following
the day such mailing is made.

SECTION 14.       ASSIGNMENT.

         This Agreement and any or all of the rights and obligations hereunder
may be assigned, delegated, sold, transferred or otherwise disposed of by the
Secured Parties by any means, including by voluntary transfer, operation of law
or otherwise, to any third person without the prior written consent of the other
parties hereto. Any such assignment, however, shall only be effective if the
assignor provides the Company with two business days' prior written notice of
such assignment. The Company's right to redeem Preferred Stock or cancel the
related Warrants pursuant to the Call Option Agreement shall survive each such
assignment, whether or not the

                                       4
Security Agreement

<PAGE>   5

related Preferred Stock or Warrant are transferred together with the transfer
of any rights under the Revenue Participation Notes or this Agreement.

SECTION 15.       GOVERNING LAW.

         This Agreement shall be governed by and construed under the laws of the
State of New York.

                                       5

<PAGE>   6

         This Agreement shall have the effect of an instrument under seal.

                                   COMPANY:

                                   AMERICAN BIOGENETIC SCIENCES, INC.

                                   By:_______________________________
                                   Josef C. Schoell
                                   President

                                   SECURED PARTIES:

                                   BIOTECHNOLOGY VALUE FUND, L.P.
                                   By:  BVF PARTNERS L.P., its General Partner
                                        By: BVF, INC., its General Partner

                                            By:  ______________________________
                                                 Mark N. Lampert
                                                 President

                                   BIOTECHNOLOGY VALUE FUND II, L.P.
                                   By:  BVF PARTNERS L.P., its General Partner
                                        By: BVF, INC., its General Partner

                                            By:  ______________________________
                                                 Mark N. Lampert
                                                 President

                                   INVESTMENT 10 L.L.C.
                                   By:  BVF PARTNERS, L.P., its Investment
                                        Advisor
                                        By: BVF, INC., its General Partner

                                            By:  ______________________________
                                                 Mark N. Lampert
                                                 President

                                   BVF INVESTMENTS L.L.C.
                                   By:  BVF PARTNERS, L.P.
                                        By: BVF, INC., its General Partner

                                            By:  ______________________________
                                                 Mark N. Lampert
                                                 President

Security Agreement<PAGE>   1
                                                                     EXHIBIT 4.8

                              CALL OPTION AGREEMENT

         This CALL OPTION AGREEMENT, dated as of the ___ day of August, 2001,
(the "Agreement") is entered into by and among AMERICAN BIOGENETIC SCIENCES,
INC., a Delaware corporation (the "Company"), and the investors signatories
hereto (individually, a "Holder," and collectively, the "Holders").

                                    RECITALS

         WHEREAS, the Company has previously issued certain Series A Convertible
Preferred Stock (the "Series A Preferred Stock") and related Series A Warrants
(the "Series A Warrants"), as to which 6,000,000 of said Series A Warrants were
amended ("Amended Series A Warrants");

         WHEREAS, each of the Holders is a party to that certain Securities
Purchase Agreement, dated as of the date hereof (the "Series B Securities
Purchase Agreement") with the Company, providing, INTER ALIA, for the purchase
by certain of the Holders of the Company's Series B Convertible Preferred Stock
(the "Series B Preferred Stock") and Series B Warrants and the amendment of the
Company's Restated Certificate of Incorporation to amend the terms of the Series
A Preferred Stock held by certain other of the Holders and to designate the
Series B Preferred Stock out of the Company's undesignated Preferred Stock;

         WHEREAS, in conjunction with the issuance of the Series B Preferred
Shares and the Series B Warrants, the Company has further agreed to grant to the
Holders certain Revenue Participation Notes, pursuant to which a portion of any
royalty payments received by the Company under a certain Exclusive License
Agreement dated January 27, 2000, as it may be amended from time to time between
the Company and Abbott Laboratories (the "Exclusive License Agreement"), will be
paid to the Holders, and Holders have agreed to grant to the Company the right
to redeem or repurchase shares of the Series A Preferred Stock and Series B
Preferred Stock and cancel and redeem the Series A Warrants and Series B
Warrants, all as more fully described herein; and

         WHEREAS, the parties hereto desire to set forth certain matters to
which they have agreed relating to the foregoing;

         NOW, THEREFORE, in consideration of the mutual promises, covenants and
conditions hereinafter set forth and for other good and valuable consideration
the Company, each Holder, severally and not jointly, hereby agree as follows:

Section 1.        CERTAIN DEFINITIONS.

         (a) As used in this Agreement, the following terms shall have the
following respective meanings:

         "Charter Amendment" means the Amended and Restated Certificate of
Incorporation filed pursuant to the Series B Securities Purchase Agreement.

Call Option Agreement
Execution Copy
<PAGE>   2

         "Holder" means each person signatory hereto who upon completion of the
sale under the Securities Purchase Agreement shall be a holder of Preferred
Stock, Warrants, and a Revenue Participation Note, and shall also include all
successors and assigns of such person's interests therein.

         "Preferred Stock" means a collective reference to the Series A
Preferred Stock and the Series B Preferred Stock.

         "Revenue Participation Note" means any of that series of Revenue
Participation Notes issued by the Company pursuant to the Series B Securities
Purchase Agreement, evidencing the right to receive certain royalty payments
received by the Company under the Exclusive License Agreement.

         "Warrants" means a collective reference to the Series A Warrants and
the Series B Warrants.

(b) Any other term capitalized herein and not defined herein shall have the
meaning specified in the Revenue Participation Notes and the Series B Securities
Purchase Agreement.

Section 2.        RIGHT TO CALL PREFERRED STOCK AND WARRANTS.

         (a) RIGHT TO CALL. Following any payment by the Company of a Fractional
Amount to any Holder of a Revenue Participation Note, the Company shall have the
right, but not the obligation, to (i) redeem such number of shares of such
Holder's Preferred Stock, or the Preferred Stock then held by such Holder's
predecessor in interest, as can be redeemed at the original purchase price
thereof for an amount equal to one-fifth (1/5th) of the amount of such
Fractional Amount paid to Holder and (ii) under the related Warrant, cancel the
right to purchase 1000 shares of Common Stock for each share of Preferred Stock
redeemed pursuant to clause (i) hereof, in exchange for a payment of $0.0125 per
Warrant share.

         (b) PRIORITY. Redemptions under this Section (including redemptions in
part) shall be made from the holders of Preferred Stock based upon the amount
paid to each Holder (or such Holder's successor in interest) under the Revenue
Participation Notes. However, all shares of Series A Preferred Stock subject to
this Agreement must be redeemed prior to any redemption of the Series B
Preferred Stock, and all Amended Series A Warrants must be cancelled hereunder
before any Series B Warrants are cancelled.

         (c) NOTICE. Notice of any election to redeem Preferred Stock or cancel
a Warrant shall be given by the Company to each holder to be redeemed at least 5
days prior to date on which it proposes to redeem the stock or cancel the
Warrant (the "Redemption Date"). Notice shall be given to the holders of record
at their respective addresses appearing on the books of the Company or given by
such holder to the Company for the purposes of notice, or if no such address
appears or is given, at the principal office of the Company. Such notice shall
state the Redemption Date to which such notice relates, the number of shares of
Preferred Stock to be

 Call Option Agreement
Execution Copy

                                       2
<PAGE>   3

redeemed or Warrants to be cancelled from all holders thereof and from such
holder, and the date on which such holder's right to convert into Common
Stock pursuant to the Charter Amendment will terminate as to such shares. On the
Redemption Date, each holder of shares of Preferred Stock shall surrender the
certificate evidencing such shares to the Company at the place designated in the
notice. If less than all the shares represented by any such surrendered
certificate have been or are being redeemed, a new certificate shall be issued
representing the unredeemed shares.

         (d) FUNDS AVAILABLE. Payments made to holders of the Revenue
Participation Notes may be used to redeem shares of Preferred Stock only to the
extent of funds legally available for redemption on any such Redemption Date. To
the extent payments made to holders of Preferred Stock pursuant to Revenue
Participation Notes exceed the amount of the funds legally available for
redemption under applicable law, the payments may be used to redeem from among
the holders of the Preferred Stock the number of shares of Preferred Stock
having an aggregate redemption price as nearly equal as possible to the amount
of the funds available therefor. For the purpose of determining whether funds
are legally available for redemption of shares of Preferred Stock as provided
herein, the Company shall value its assets at the highest amount reasonably
permissible under applicable law.

         (e) RIGHTS CEASE. From and after the Redemption Date, and upon payment
by the Company of the redemption price then, notwithstanding that the
certificates evidencing any shares of Preferred Stock so called for redemption
shall not have been surrendered, all rights of the holders thereof with respect
to the shares so called for redemption shall forthwith after such date cease and
terminate.

Section 3.        MISCELLANEOUS.

         (a) NOTICES. All notices, requests, consents and other communications
hereunder shall be in writing, shall be addressed to the receiving party's
address set forth in Section 10.1 of the Series B Securities Purchase Agreement
or to such other address as a party may designate by notice hereunder, and shall
be either (i) delivered by hand, (ii) made by telecopy or facsimile
transmission, (iii) sent by recognized national overnight courier service, or
(iv) sent by registered mail, return receipt requested, postage prepaid. All
notices, requests, consents and other communications hereunder shall be deemed
to have been given either (i) if by hand, at the time of the delivery thereof to
the receiving party at the address of such party set forth above, (ii) if made
by telecopy or facsimile transmission, on the next business day after the time
that receipt thereof has been acknowledged by electronic confirmation or
otherwise, (iii) if sent by overnight courier, on the next business day
following the day such notice is delivered to the courier service, or (iv) if
sent by registered mail, on the fifth business day following the day such
mailing is made.

         (b) ENTIRE AGREEMENT. This Agreement, together with the Securities
Purchase Agreement and such other documents as are referred to therein, embodies
the entire agreement and understanding between the parties hereto with respect
to the subject matter hereof and supersedes all prior oral or written agreements
and understandings relating to the subject matter hereof. No statement,
representation, warranty, covenant or agreement of any kind not expressly

Call Option Agreement
Execution Copy

                                       3
<PAGE>   4

set forth in this Agreement shall affect, or be used to interpret, change or
restrict, the express terms and provisions of this Agreement.

         (c) AMENDMENTS. The terms and provisions of the Agreement may be
modified, amended or waived, or consent for the departure therefrom granted,
only by written agreement of the Company; and Holders holding in the aggregate a
majority of the Fractional Percentage held by all Holders of Revenue
Participation Notes. No such waiver or consent, in either case, shall be deemed
to be or shall constitute a waiver or consent with respect to any other terms or
provisions of this Agreement, whether or not similar. Each such waiver or
consent, in either case, shall be effective only in the specific instance and
for the purpose for which it was given, and shall not constitute a continuing
waiver or consent.

         (d) ASSIGNMENT. This Agreement and any or all of the rights and
obligations of a party hereunder may be assigned, delegated, sold, transferred
or otherwise disposed of by any means, including by voluntary transfer,
operation of law or otherwise, to any third person without the prior written
consent of the other parties hereto. Any such assignment, however, shall only be
effective if the assignor provides the Company with two business days' prior
written notice of such assignment. The Company's right to redeem Preferred Stock
or cancel the related Warrants shall survive each such assignment, whether or
not the related Preferred Stock or Warrant are transferred together with any
transfer of a Revenue Participation Note. Each party shall be responsible for
the compliance by its affiliates with the terms and conditions of this
Agreement.

         (e) BENEFIT. All statements, representations, warranties, covenants and
agreements in this Agreement shall be binding on the parties hereto and shall
inure to the benefit of the respective successors and permitted assigns of each
party hereto. Nothing in this Agreement shall be construed to create any rights
or obligations except among the parties hereto, and no person or entity shall be
regarded as a third-party beneficiary of this Agreement.

         (f) GOVERNING LAW. This Agreement and the rights and obligations of the
parties hereunder shall be construed in accordance with and governed by the law
of the State of New York except that the law of the State of Delaware shall be
applicable with respect to corporate matters.

         (g) SEVERABILITY. In the event that any court of competent jurisdiction
shall determine that any provision, or any portion thereof, contained in this
Agreement shall be unreasonable or unenforceable in any respect, then such
provision shall be deemed limited to the extent that such court deems it
reasonable and enforceable, and as so limited shall remain in full force and
effect. In the event that such court shall deem any such provision, or portion
thereof, wholly unenforceable, the remaining provisions of this Agreement shall
be interpreted as if such provision were so excluded and shall nevertheless
remain in full force and effect.

         (h) HEADINGS AND CAPTIONS. The headings and captions of the various
subdivisions of this Agreement are for convenience of reference only and shall
in no way modify, or affect the meaning or construction of any of the terms or
provisions hereof.

Call Option Agreement
Execution Copy

                                       4
<PAGE>   5

         (i) NO WAIVER OF RIGHTS, POWERS AND REMEDIES. No failure or delay by a
party hereto in exercising any right, power or remedy under this Agreement, and
no course of dealing between the parties hereto, shall operate as a waiver of
any such right, power or remedy of the party. No single or partial exercise of
any right, power or remedy under this Agreement by a party hereto, nor any
abandonment or discontinuance of steps to enforce any such right, power or
remedy, shall preclude such party from any other or further exercise thereof or
the exercise of any other right, power or remedy hereunder. The election of any
remedy by a party hereto shall not constitute a waiver of the right of such
party to pursue other available remedies. No notice to or demand on a party not
expressly required under this Agreement shall entitle the party receiving such
notice or demand to any other or further notice or demand in similar or other
circumstances or constitute a waiver of the rights of the party giving such
notice or demand to any other or further action in any circumstances without
such notice or demand.

         (j) COUNTERPARTS. This Agreement may be executed in one or more
counterparts, and by different parties hereto on separate counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

         (k) FURTHER ASSURANCES. In case any further action is necessary or
desirable to carry out the purposes of this Agreement, the Company and the
Holders will take such further action as the other party may reasonably request,
all at the sole cost and expense of the requesting party.

                     [REST OF PAGE INTENTIONALLY LEFT BLANK]

Call Option Agreement
Execution Copy

                                       5

<PAGE>   6

         IN WITNESS WHEREOF, the undersigned have executed this Call Option
Agreement as of this ___ day of August, 2001.

                                      AMERICAN BIOGENETIC SCIENCES, INC.

                                      By:
                                          --------------------------------------
                                          Name:    Josef C. Schoell
                                          Title:   President, COO and CFO

                                      HOLDERS:

                                      BIOTECHNOLOGY VALUE FUND, L.P.
                                      By: BVF PARTNERS L.P., its General Partner
                                          By: BVF, INC., its General Partner

                                              By:  _____________________________
                                                   Mark N. Lampert
                                                   President

                                      BIOTECHNOLOGY VALUE FUND II, L.P.
                                      By: BVF PARTNERS L.P., its General Partner
                                          By: BVF, INC., its General Partner

                                              By:  _____________________________
                                                   Mark N. Lampert
                                                   President

                                      INVESTMENT 10 L.L.C.
                                      By: BVF PARTNERS, L.P., its Investment
                                          Advisor
                                          By: BVF, INC., its General Partner

                                              By:  _____________________________
                                                   Mark N. Lampert
                                                   President

                                      BVF INVESTMENTS, L.L.C.
                                      By: BVF PARTNERS, L.P., its Investment
                                          Advisor
                                          By: BVF, INC., its General Partner

                                              By:  _____________________________
                                                   Mark N. Lampert
                                                   President

Call Option Agreement
Execution Copy

                                       6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}]]